Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Unger Takes Over ODE I As Acting Director; Temple To Focus On Clinical Science Role

This article was originally published in The Pink Sheet Daily

Advertisement

Related Content

Invaluable Guidance: FDA’s Dean of Drug Reviews on “Enrichment Strategies”
Chelsea Took Proactive PR Approach For Northera Panel, But Will It Help Or Hurt?
FDA’s Temple Sees Sentinel As Important Tool For Confirming And Analyzing Drug Adverse Events
Rare Diseases Need Ongoing Natural History Studies To Speed Trials, FDA Says
Pradaxa Review Shows FDA Doubts About The Power Of REMS To Change Prescribing Practices
FDA, EMA Decisions On Avandia Reflect The Power Of REMS
FDA's Marciniak vs. Unger: Cardio Experts Divided On GSK's RECORD Study

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073322

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel